Summary

The North America flow cytometry market is expected to reach USD 7.77 billion by 2032 from USD 3.40 billion in 2024, growing at a CAGR of 10.8% in the forecast period of 2025 to 2032.
Market Segmentation:
North America Flow Cytometry Market, By Product (Reagents and Consumables, Flow Cytometry Instruments, Accessories, Services, and Software), Technology (Cell-Based Flow Cytometry and Bead-Based Flow Cytometry), Application (Research Applications, Clinical Applications, and Industrial Applications), End user (Pharmaceuticals and Biotechnology Companies, Academic & Research Institutes, Hospitals, Clinical Testing Laboratories, CRO, Blood Bank, CMO & CDMO, Forensic Laboratories, and Others), Distribution Channel (Retail Sales and Direct Tenders), Country (U.S., Canada, and Mexico) - Industry Trends & Forecast To 2032

Overview of North America Flow Cytometry Market Dynamics:

Driver
• Rising Prevalence of Chronic Diseases
Restrain

• High Cost of Flow Cytometry Instruments

Opportunity

• Increase in Adoption of Flow Cytometry Techniques in Research and Academia

Market Players:

The key market players operating in the North America flow cytometry market are listed below:

• BD
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• Sartorius AG
• Bennubio Inc.
• Enzo Biochem Inc.
• Apogee Flow Systems Ltd.
• Beckman Coulter, Inc.
• Coherent Corp.
• Cell Signaling Technology, Inc.
• Cytek Biosciences
• Biomérieux
• Cytonome/ST LLC

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 74
1.1 OBJECTIVES OF THE STUDY 74
1.2 MARKET DEFINITION 74
1.3 OVERVIEW OF THE NORTH AMERICA FLOW CYTOMETRY MARKET 74
1.4 CURRENCY AND PRICING 76
1.5 LIMITATIONS 76
1.6 MARKETS COVERED 76
2 MARKET SEGMENTATION 79
2.1 MARKETS COVERED 79
2.2 GEOGRAPHICAL SCOPE 80
2.3 YEARS CONSIDERED FOR THE STUDY 81
2.4 DBMR TRIPOD DATA VALIDATION MODEL 82
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 85
2.6 MULTIVARIATE MODELLING 86
2.7 DBMR MARKET POSITION GRID 87
2.8 VENDOR SHARE ANALYSIS 88
2.9 SECONDARY SOURCES 89
2.10 ASSUMPTIONS 89
3 EXECUTIVE SUMMARY 90
4 PREMIUM INSIGHTS 95
4.1 PESTAL ANALYSIS 96
4.2 PORTERS FIVE FORCES ANALYSIS 97
5 NORTH AMERICA FLOW CYTOMETRY MARKET: REGULATIONS 98
6 MARKET OVERVIEW 100
6.1 DRIVERS 102
6.1.1 RISING PREVALENCE OF CHRONIC DISEASES 102
6.1.2 INCREASING APPLICATION OF CYTOMETRY INSTRUMENTS 103
6.1.3 GROWING USE OF FLOW CYTOMETRY IN DRUG DISCOVERY 104
6.1.4 GROWING RESEARCH FUNDING 105
6.2 RESTRAINTS 106
6.2.1 HIGH COST OF FLOW CYTOMETRY INSTRUMENTS 106
6.2.2 LIMITATIONS OF FLOW CYTOMETRY 106
6.3 OPPORTUNITIES 108
6.3.1 INCREASE IN ADOPTION OF FLOW CYTOMETRY TECHNIQUES IN RESEARCH AND ACADEMIA 108
6.3.2 RISING DEVELOPMENT OF PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES 108
6.3.3 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS 109
6.4 CHALLENGES 110
6.4.1 DIFFICULTY IN THE DEVELOPMENT AND VALIDATION OF FLOW CYTOMETRY ASSAYS 110
6.4.2 COMPLEXITIES RELATED TO REAGENT DEVELOPMENT 110
7 NORTH AMERICA FLOW CYTOMETRY MARKET, BY PRODUCT 112
7.1 OVERVIEW 113
7.2 REAGENTS AND CONSUMABLES 116
7.2.1 DYE 117
7.2.2 ANTIBODIES 117
7.2.3 BEADS 117
7.2.4 OTHERS 117
7.3 FLOW CYTOMETRY INSTRUMENTS 117
7.3.1 CELL ANALYZERS 119
7.3.1.1 CELL ANALYZERS, BY TYPE 119
7.3.1.1.1 IMAGING FLOW CYTOMETERS 119
7.3.1.1.2 NON-IMAGING FLOW CYTOMETERS 119
7.3.1.2 CELL ANALYZERS, BY RANGE 120
7.3.1.2.1 HIGH-RANGE CELL ANALYZERS 120
7.3.1.2.2 MID-RANGE CELL ANALYZERS 120
7.3.1.2.3 LOW-RANGE CELL ANALYZERS 120
7.3.1.3 CELL ANALYZERS, BY MODALITY 120
7.3.1.3.1 BENCHTOP 121
7.3.1.3.2 STANDALONE 121
7.3.2 CELL SORTERS 121
7.3.2.1 BENCHTOP 121
7.3.2.2 STANDALONE 121
7.3.3 CELL SORTERS 121
7.3.3.1 HIGH-RANGE CELL ANALYZERS 122
7.3.3.2 MID-RANGE CELL ANALYZERS 122
7.3.3.3 LOW-RANGE CELL ANALYZERS 122
7.4 ACCESSORIES 123
7.4.1 FILTERS 124
7.4.2 DETECTORS 124
7.4.3 OTHERS 124
7.5 SERVICES 125
7.6 SOFTWARE 125
8 NORTH AMERICA FLOW CYTOMETRY MARKET, BY TECHNOLOGY 126
8.1 OVERVIEW 127
8.2 CELL-BASED FLOW CYTOMETRY 130
8.2.1 FLOW CYTOMETRY INSTRUMENTS 131
8.2.2 REAGENTS & CONSUMABLES 131
8.2.3 ACCESSORIES 131
8.3 BEAD-BASED FLOW CYTOMETRY 131
8.3.1 FLOW CYTOMETRY INSTRUMENTS 131
8.3.2 REAGENTS & CONSUMABLES 131
8.3.3 ACCESSORIES 131
9 NORTH AMERICA FLOW CYTOMETRY MARKET, BY APPLICATION 132
9.1 OVERVIEW 133
9.2 RESEARCH APPLICATIONS 136
9.2.1 CELL CYCLE ANALYSIS 137
9.2.2 CELL SORTING/SCREENING 137
9.2.3 CELL TRANSFECTION/VIABILITY 137
9.2.4 PHARMACEUTICAL AND BIOTECHNOLOGY 137
9.2.4.1 DRUG DISCOVERY 137
9.2.4.2 STEM CELL RESEARCH 137
9.2.4.3 IN VITRO TOXICITY TESTING 137
9.2.5 IMMUNOLOGY 138
9.2.6 APOPTOSIS 138
9.2.7 CELL COUNTING 138
9.2.8 OTHERS 138
9.3 CLINICAL APPLICATIONS 138
9.3.1 HAEMATOLOGY 139
9.3.2 CANCER 139
9.3.3 IMMUNODEFICIENCY DISEASES 139
9.3.4 ORGAN TRANSPLANTATION 139
9.3.5 OTHER CLINICAL APPLICATION 139
9.4 INDUSTRIAL APPLICATIONS 139
10 NORTH AMERICA FLOW CYTOMETRY MARKET, BY DISTRIBUTION CHANNEL 140
10.1 OVERVIEW 141
10.2 RETAIL SALES 144
10.2.1 OFFLINE 144
10.2.2 ONLINE 144
10.3 DIRECT TENDERS 145
11 NORTH AMERICA FLOW CYTOMETRY MARKET, BY END USER 146
11.1 OVERVIEW 147
11.2 PHARMACEUTICALS AND BIOTECHNOLOGY COMPANIES 150
11.3 ACADEMIC & RESEARCH INSTITUTES 151
11.4 HOSPITALS 151
11.5 CLINICAL TESTING LABORATORIES 152
11.6 CRO 152
11.7 BLOOD BANK 153
11.8 CMO & CDMO 153
11.9 FORENSIC LABORATORIES 154
11.10 Others 154
12 NORTH AMERICA FLOW CYTOMETRY MARKET, BY REGION 155
12.1 NORTH AMERICA 157
12.1.1 U.S. 166
12.1.2 CANADA 175
12.1.3 MEXICO 183
13 NORTH AMERICA FLOW CYTOMETRY MARKET: COMPANY LANDSCAPE 191
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS 192
15 COMPANY PROFILES 193
15.1 BD 193
15.1.1 COMPANY SNAPSHOT 193
15.1.2 REVENUE ANALYSIS 193
15.1.3 COMPANY SHARE ANALYSIS 194
15.1.4 PRODUCT PORTFOLIO 194
15.1.5 RECENT DEVELOPMENT 197
15.2 AGILENT TECHNOLOGIES, INC. 198
15.2.1 COMPANY SNAPSHOT 198
15.2.2 REVENUE ANALYSIS 198
15.2.3 COMPANY SHARE ANALYSIS 199
15.2.4 PRODUCT PORTFOLIO 199
15.2.5 RECENT DEVELOPMENT 201
15.3 THERMO FISHER SCIENTIFIC INC 202
15.3.1 COMPANY SNAPSHOT 202
15.3.2 REVENUE ANALYSIS 203
15.3.3 COMPANY SHARE ANALYSIS 203
15.3.4 PRODUCT PORTFOLIO 203
15.3.5 RECENT DEVELOPMENT 206
15.4 BIO-RAD LABORATORIES, INC. 207
15.4.1 COMPANY SNAPSHOT 207
15.4.2 REVENUE ANALYSIS 207
15.4.3 COMPANY SHARE ANALYSIS 208
15.4.4 PRODUCT PORTFOLIO 208
15.4.5 RECENT DEVELOPMENT 209
15.5 SARTORIUS AG 210
15.5.1 COMPANY SNAPSHOT 210
15.5.2 REVENUE ANALYSIS 211
15.5.3 COMPANY SHARE ANALYSIS 211
15.5.4 PRODUCT PORTFOLIO 211
15.5.5 RECENT DEVELOPMENT 213
15.6 APOGEE FLOW SYSTEMS LTD. 214
15.6.1 COMPANY SNAPSHOT 214
15.6.2 PRODUCT PORTFOLIO 214
15.6.3 RECENT DEVELOPMENT 214
15.7 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER CORPORATION) 215
15.7.1 COMPANY SNAPSHOT 215
15.7.2 REVENUE ANALYSIS 215
15.7.3 PRODUCT PORTFOLIO 216
15.7.4 RECENT DEVELOPMENT 217
15.8 BIOMÉRIEUX 219
15.8.1 COMPANY SNAPSHOT 219
15.8.2 REVENUE ANALYSIS 219
15.8.3 PRODUCT PORTFOLIO 220
15.8.4 RECENT DEVELOPMENT 220
15.9 BIOLEGEND, INC. 221
15.9.1 COMPANY SNAPSHOT 221
15.9.2 PRODUCT PORTFOLIO 221
15.9.3 RECENT DEVELOPMENT 221
15.10 BENNUBIO INC 222
15.10.1 COMPANY SNAPSHOT 222
15.10.2 PRODUCT PORTFOLIO 222
15.10.3 RECENT DEVELOPMENT 222
15.11 COHERENT CORP. 223
15.11.1 COMPANY SNAPSHOT 223
15.11.2 REVENUE ANALYSIS 223
15.11.3 PRODUCT PORTFOLIO 224
15.11.4 RECENT DEVELOPMENT 224
15.12 CYTONOME/ST, LLC 225
15.12.1 COMPANY SNAPSHOT 225
15.12.2 PRODUCT PORTFOLIO 225
15.12.3 RECENT DEVELOPMENTS 226
15.13 CYTOBUOY 227
15.13.1 COMPANY SNAPSHOT 227
15.13.2 PRODUCT PORTFOLIO 227
15.13.3 RECENT DEVELOPMENT 228
15.14 CELL SIGNALING TECHNOLOGY, INC 229
15.14.1 COMPANY SNAPSHOT 229
15.14.2 PRODUCT PORTFOLIO 229
15.14.3 RECENT DEVELOPMENT 230
15.15 CYTEK BIOSCIENCES 231
15.15.1 COMPANY SNAPSHOT 231
15.15.2 PRODUCT PORTFOLIO 231
15.15.3 RECENT DEVELOPMENT 232
15.16 DIASORIN S.P.A. 233
15.16.1 COMPANY SNAPSHOT 233
15.16.2 REVENUE ANALYSIS 233
15.16.3 PRODUCT PORTFOLIO 234
15.16.4 RECENT DEVELOPMENT 234
15.17 ELABSCIENCE BIONOVATION INC. 235
15.17.1 COMPANY SNAPSHOT 235
15.17.2 PRODUCT PORTFOLIO 235
15.17.3 RECENT DEVELOPMENT 236
15.18 ENZO BIOCHEM, INC 237
15.18.1 COMPANY SNAPSHOT 237
15.18.2 REVENUE ANALYSIS 237
15.18.3 PRODUCT PORTFOLIO 238
15.18.4 RECENT DEVELOPMENT 239
15.19 MILTENYI BIOTEC AND/OR ITS AFFILIATES 240
15.19.1 COMPANY SNAPSHOT 240
15.19.2 PRODUCT PORTFOLIO 240
15.19.3 RECENT DEVELOPMENT 242
15.20 MERCK KGAA 243
15.20.1 COMPANY SNAPSHOT 243
15.20.2 REVENUE ANALYSIS 243
15.20.3 PRODUCT PORTFOLIO 244
15.20.4 RECENT DEVELOPMENT 245
15.21 NANOCELLECT BIOMEDICAL 246
15.21.1 COMPANY SNAPSHOT 246
15.21.2 PRODUCT PORTFOLIO 246
15.21.3 RECENT DEVELOPMENTS 247
15.22 NEOGENOMICS LABORATORIES 249
15.22.1 COMPANY SNAPSHOT 249
15.22.2 REVENUE ANALYSIS 250
15.22.3 PRODUCT PORTFOLIO 250
15.22.4 RECENT DEVELOPMENT 250
15.23 ON-CHIP BIOTECHNOLOGIES CO., LTD. CORPORATION 251
15.23.1 COMPANY SNAPSHOT 251
15.23.2 PRODUCT PORTFOLIO 251
15.23.3 RECENT DEVELOPMENTS 252
15.24 ORLFO TECHNOLOGIES 253
15.24.1 COMPANY SNAPSHOT 253
15.24.2 PRODUCT PORTFOLIO 253
15.24.3 RECENT DEVELOPMENT 253
15.25 STRATEDIGM, INC 254
15.25.1 COMPANY SNAPSHOT 254
15.25.2 PRODUCT PORTFOLIO 254
15.25.3 RECENT DEVELOPMENTS 255
15.26 SONY BIOTECHNOLOGY INC 256
15.26.1 COMPANY SNAPSHOT 256
15.26.2 PRODUCT PORTFOLIO 256
15.26.3 RECENT DEVELOPMENT 258
15.27 SYSMEX ASIA PACIFIC PTE LTD (PART OF SYSMEX CORPORATION) 259
15.27.1 COMPANY SNAPSHOT 259
15.27.2 REVENUE ANALYSIS 259
15.27.3 PRODUCT PORTFOLIO 260
15.27.4 RECENT DEVELOPMENT 261
15.28 TAKARA BIO INC. 262
15.28.1 COMPANY SNAPSHOT 262
15.28.2 PRODUCT PORTFOLIO 262
15.28.3 RECENT DEVELOPMENT 263
15.29 UNION BIOMETRICA, INC. 264
15.29.1 COMPANY SNAPSHOT 264
15.29.2 PRODUCT PORTFOLIO 264
15.29.3 RECENT DEVELOPMENTS 265
16 QUESTIONNAIRE 267
17 RELATED REPORTS 270